AZD2461: Novel PARP Inhibitor for Breast Cancer DNA Repair Research

Executive Summary: AZD2461 is a highly potent poly (ADP-ribose) polymerase (PARP) inhibitor with an IC₅₀ of 5 nM against PARP-1, showing strong cytotoxicity in human breast cancer cell lines (MCF-7, SKBR-3) via G2-phase cell cycle arrest and reduction in S-phase cell populations (Schwartz 2022). In vivo, AZD2461 inhibits PARP activity in KB1P tumor-bearing mice for several hours post-administration, with pharmacodynamic effects receding by 24 hours. The compound exhibits a lower binding affinity for P-glycoprotein (Pgp) than olaparib, suggesting efficacy in Pgp-mediated drug-resistant contexts. AZD2461 is well tolerated with long-term dosing and significantly prolongs median relapse-free survival in mouse models. As a solid with a molecular weight of 395.43 and insolubility in water, AZD2461 is soluble in DMSO (≥16.35 mg/mL) and ethanol (≥45.2 mg/mL with ultrasonic assistance), making it compatible with standard in vitro workflows (APExBIO).

Biological Rationale

Poly (ADP-ribose) polymerase (PARP) enzymes, such as PARP-1, play a central role in DNA repair via the base excision repair pathway. Inhibiting PARP activity leads to accumulation of DNA strand breaks, especially lethal in cells with defective homologous recombination repair, such as BRCA1-mutated breast cancer cells (Schwartz 2022). This synthetic lethality is the basis for using PARP inhibitors in targeted cancer therapies. AZD2461 selectively targets PARP-1, disrupting DNA repair, which results in cell cycle arrest and apoptosis. The compound's low affinity for Pgp addresses a key resistance mechanism in cancer therapy, allowing improved intracellular retention and cytotoxicity in drug-resistant cancer phenotypes (Related Article; this article details how AZD2461’s Pgp profile extends previously described mechanisms).

Mechanism of Action of AZD2461

AZD2461 is a potent inhibitor of PARP-1, with an IC₅₀ of 5 nM in biochemical assays (APExBIO). Upon entry into breast cancer cells, AZD2461 binds to the catalytic domain of PARP-1, preventing poly (ADP-ribosyl)ation of target proteins. This inhibition halts repair of single-strand DNA breaks, triggering replication-dependent double-strand breaks, particularly in S-phase. As a result, cells accumulate DNA damage, leading to cell cycle arrest predominantly in the G2 phase and a reduction in the S-phase population. This mechanism is validated in MCF-7 and SKBR-3 breast cancer cell lines, where AZD2461 reduces cell viability in a concentration- and time-dependent manner (5–50 μM, 48–72 h). In vivo, AZD2461 administration in mice with BRCA1-deficient tumors leads to rapid PARP inhibition and subsequent reduction in PAR levels, with effects dissipating by 24 hours post-dose (Related Guide; this guide benchmarks in vivo efficacy and extends on workflow integration described here).

Evidence & Benchmarks

• AZD2461 inhibits PARP-1 activity with an IC₅₀ of 5 nM in in vitro biochemical assays (APExBIO).
• In human breast cancer cell lines MCF-7 and SKBR-3, AZD2461 reduces viable cell numbers in a concentration-dependent manner (5–50 μM, 48–72 h) (Schwartz 2022).
• AZD2461 induces G2-phase cell cycle arrest and decreases S-phase populations, indicating DNA damage checkpoint activation (Schwartz 2022).
• In KB1P mouse tumor models, AZD2461 rapidly inhibits PARP activity for several hours, with PAR levels returning to baseline by 24 h post-dosing (Schwartz 2022).
• AZD2461 demonstrates lower affinity for P-glycoprotein than olaparib, making it effective in Pgp-mediated drug-resistant cancer cells (Strategic Analysis; this article clarifies resistance mechanisms compared to the present work).
• Long-term AZD2461 administration in mice is well tolerated and extends median relapse-free survival in preclinical tumor models (Schwartz 2022).

Applications, Limits & Misconceptions

AZD2461 is employed in breast cancer research, particularly in studies targeting DNA repair pathway modulation and overcoming Pgp-mediated drug resistance. It is especially suitable for BRCA1-mutated tumor models, where synthetic lethality can be exploited. The compound’s solubility profile supports compatibility with a variety of in vitro and in vivo protocols. However, several boundaries and misconceptions exist regarding its use.

Common Pitfalls or Misconceptions

• Not suitable for water-based stock solutions: AZD2461 is insoluble in water; use DMSO or ethanol (with sonication) for stocks (APExBIO).
• Short-term solution stability: Once prepared, AZD2461 solutions should be used promptly; extended storage leads to potency loss.
• Effect limited to PARP-dependent DNA repair: Cells with intact homologous recombination, such as wild-type BRCA1/2, may not exhibit the same cytotoxic response.
• Does not universally overcome all drug resistance: While Pgp-mediated resistance is addressed, other mechanisms (e.g., alternative efflux pumps) may still affect efficacy.
• Optimal concentrations and incubation times are context-dependent: Exceeding 50 μM or 72 h may introduce off-target or cytostatic effects unrelated to PARP inhibition.

Workflow Integration & Parameters

For in vitro studies, AZD2461 is typically dissolved in DMSO at ≥16.35 mg/mL or ethanol at ≥45.2 mg/mL with ultrasonic assistance. Recommended experimental concentrations range from 5 to 50 μM, with incubation times of 48 to 72 hours for breast cancer cell line assays. The compound should be stored at -20°C as a solid, and aliquots should be prepared fresh for each experiment to ensure chemical integrity. For in vivo studies, AZD2461 has been validated in BRCA1-deficient mouse tumor models, where it is administered via appropriate routes and schedules to produce sustained PARP inhibition and monitor pharmacodynamic endpoints (e.g., PAR levels, relapse-free survival). For expanded protocols and troubleshooting, see AZD2461: A Novel PARP Inhibitor Advancing Breast Cancer Research (this article provides updated integration strategies, expanding on in vitro benchmarks presented here).

Conclusion & Outlook

AZD2461, offered by APExBIO, is a robust tool for investigating PARP signaling pathway modulation and synthetic lethality in breast cancer research. Its unique pharmacological profile—marked by potent PARP-1 inhibition, low Pgp affinity, and efficacy in relapse-free survival extension—sets it apart from legacy PARP inhibitors. As in vitro and in vivo benchmarking protocols evolve, AZD2461’s integration into multi-parametric drug evaluation workflows will help clarify resistance mechanisms and optimize personalized cancer therapies. For further comparison with related compounds and extended best practices, see AZD2461 and the Next Frontier of PARP Inhibition, which synthesizes advanced applications and translational opportunities that build upon the experimental data reviewed here.